Skip to main content

Drug Interactions between fluconazole and irbesartan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

fluconazole irbesartan

Applies to: fluconazole and irbesartan

The concomitant administration of fluconazole may modestly increase irbesartan concentrations. The proposed mechanism is inhibition of CYP450 2C9 mediated metabolism by fluconazole. After irbesartan 150 mg/day and fluconazole 200 mg/day were administered concurrently for 10 days to healthy subjects (n=15), mean irbesartan maximum plasma concentrations (Cmax) increased by 19% and areas under the concentration-time curve (AUC) increased by 63%. The clinical significance is unknown.

References (2)
  1. Marino MR, Vachharajani NN (2001) "Drug interactions with irbesartan." Clin Pharmacokinet, 40, p. 605-14
  2. Kovacs SJ, Wilton JH, Blum RA (1999) "Steady state (SS) pharmacokinetics (PK) of irbesartan alone and in combination with fluconazole." Clin Pharmacol Ther, 65, p. 132

Drug and food interactions

Moderate

irbesartan food

Applies to: irbesartan

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.

References (2)
  1. (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
  2. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer